AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03676985
Drug: ZKAB001 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03676985
Drug: ZKAB001 15mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT01602198
Drug: Placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch 1/day for 6 months
Trial: NCT01077531
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for intravenous infusion
Trial: NCT00369785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
Trial: NCT02946632
Drug: triple combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
Trial: NCT02946632
Drug: Stepwise add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin -\> glimepirde -\> sitagliptin
Trial: NCT00048620
Drug: N-acetylgalactosamine 4-sulfatase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
Trial: NCT00244842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01203254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet: 3 times daily 2 tablets
Trial: NCT03849027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
Trial: NCT01178255
Drug: homeopathic q-potencies
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individualised homeopathic medicines
Trial: NCT01178255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01948310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
Trial: NCT01483586
Drug: kanglaite gelcap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
Trial: NCT01483586
Drug: Kanglaite gelcap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
Trial: NCT03607643
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
Trial: NCT04199741
Drug: SC16.56, Phase I, Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg
Trial: NCT03875560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive
Trial: NCT03788395
Drug: Symbicort Turbohaler without Turbo+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
Trial: NCT01910116
Drug: Shinbaro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
Trial: NCT01910116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication and placebo were identical in appearance.
Trial: NCT02528422
Drug: Acyl-Ghrelin
RxNorm normalized name: gellan gum (low acyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03194217
Drug: BEN-2001
RxNorm normalized name: Pen-Ben
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavisant dihydrochloride monohydrate for oral use
Trial: NCT03194217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01237340
Drug: Saizen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
Trial: NCT01507454
Drug: estradiol, 25 mcg
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal tablets for 6-12 weeks according to product labelling
Trial: NCT02375646
Drug: LMW Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01856374
Drug: Pravastatin 20mg
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Trial: NCT01236118
Drug: LY2439821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT03712228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer without active ingredient
Trial: NCT01652261
Drug: BEACOPPesc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02038829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02038829
Drug: SUN101 3 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUN-101 3 mcg bid
Trial: NCT00913588
Drug: Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913588
Drug: Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913588
Drug: Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04001205
Drug: Anticoagulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Trial: NCT03476746
Drug: LEO 90100 foam
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A foam formulation of the active comparator Dovobet® ointment
Trial: NCT03476746
Drug: Dovobet® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment formulation containing same active ingredients as LEO 90100 foam
Trial: NCT02077751
Drug: biotin labelled RBCs
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
Trial: NCT02266966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02742467
Drug: Perindopril plus Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2
Trial: NCT02079922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
Trial: NCT02079922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Trial: NCT04509674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02742467
Drug: Amlodipine plus Hydrochlorothiazide
RxNorm normalized name: amlodipine / hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3
Trial: NCT00331123
Drug: Testosterone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
Trial: NCT00331123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch,changed every 3-4 days for 24 weeks during double blind phase
Trial: NCT00268307
Drug: Autologous, Unfractionated Bone Marrow Mononuclear Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
Trial: NCT00732771
Drug: LCI699
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04150588
Drug: Efrin drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount that the eyelid rise after Erin drops before surgery
Trial: NCT00821990
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
Trial: NCT04336228
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg placebo tablet daily for 3-4 weeks.
Trial: NCT03845322
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
Trial: NCT00335270
Drug: fos-amprenavir calcium, ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00955383
Drug: GSK2190915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Trial: NCT00955383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00240474
Drug: Telmisartan 80 mg + hydrochlorothiazide 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240474
Drug: Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02497976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01389206
Drug: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Trial: NCT02561585
Drug: LEO 124249
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00847119
Drug: capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
Trial: NCT01903525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
Trial: NCT00107926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00875277
Drug: LEO 29102 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00875277
Drug: LEO 29102 Cream Vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00875277
Drug: Daivobet® Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00930982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of matching placebo twice a day
Trial: NCT02276911
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01289782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
Trial: NCT01289782
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
Trial: NCT02093026
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Trial: NCT02093026
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive folic acid \>= 5 mg/week or equivalent.
Trial: NCT02483533
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02483533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01686802
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01255787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching tablets
Trial: NCT00524849
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zometa 4 mg every four weeks (intravenous)
Trial: NCT02029599
Drug: Fang yi qing feng shi granule
RxNorm normalized name: qing feng teng stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g, Oral,Three each time, 3 times a day,for 3 months;
Trial: NCT02029599
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g, Oral,Three each time, 3 times a day,for 3 months
Trial: NCT02029599
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5-15mg per week，All patients should be used
Trial: NCT02029599
Drug: Acetaminophen tablets
RxNorm normalized name: Acetaminophen Tablets
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral,0.5g, 1\~2 times a day, when vas=10
Trial: NCT02238171
Drug: Atrovent® inhalets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02951845
Drug: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
RxNorm normalized name: DIRECT BLUE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
Trial: NCT02538003
Drug: LCB01-0371 Tablet 800 mg(R)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference: taken drug before meal
Trial: NCT03101267
Drug: ASP4070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination at 2-week intervals
Trial: NCT02538003
Drug: LCB01-0371 Tablet 800 mg(T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test: taken drug after meal
Trial: NCT03101267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination at 2-week intervals
Trial: NCT00911625
Drug: 0.5 units/kg daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Trial: NCT00911625
Drug: 0.25 units/kg daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Trial: NCT00936091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 children received placebo capsules
Trial: NCT04744883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
Trial: NCT02937974
Drug: Xuebijing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Trial: NCT02937974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Trial: NCT04499235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT00941577
Drug: AIR645
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Trial: NCT00941577
Drug: Physiologic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Trial: NCT01190787
Drug: velcade cyclophosphamide prednisone
RxNorm normalized name: Velcade
DrugBank: Bortezomib D-mannitol (DB16741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
Trial: NCT03239691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo available as matching capsules for oral administration
Trial: NCT02176642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet taken by mouth daily for 6 weeks
Trial: NCT01592227
Drug: Marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed paracetamol
Trial: NCT01592227
Drug: Experimental paracetamol formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental paracetamol formulation
Trial: NCT03363464
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide-1 receptor agonist
Trial: NCT02312427
Drug: Suspending DPP-4 inhibitor, in outpatient service
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
Trial: NCT04080076
Drug: Acthar 80 UNT/ML Injectable Solution
RxNorm normalized name: Acthar 80 UNT/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTHar 80 Units SQ 1042 x Week
Trial: NCT04132375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Trial: NCT00245583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablet
Trial: NCT00829283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill daily
Trial: NCT00393835
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00665626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, twice-a-day
Trial: NCT00825851
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00322153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral administration once daily.
Trial: NCT01000961
Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
RxNorm normalized name: cysteamine Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks